How to Localize Labels and Instructions for Overseas Registration of Sterilization and Disinfection Equipment

Quick Summary

When registering sterilization and disinfection equipment overseas, localizing labels and instructions is not a simple translation exercise but a regulatory transformation and evidence-chain reconstruction. Companies must first determine whether the target country regulates the product as a medical device, then identify the risk class and corresponding registration pathway and applicant. They should also assess whether existing technical documentation such as CE, FDA, NMPA, or ISO 13485 can be reused. Labels and instructions must comply with target-country language, units of measure, symbols, warnings, manufacturer and agent information, UDI or product coding requirements. Evidence like sterilization validation, biocompatibility, and performance testing must be adjusted to local regulations. Common risks include omission of a local agent or authorized representative leading to submission failure; labels lacking the local registration number causing customs detention; intended-use statements in the instructions inconsistent with the registered application triggering post-market review; and incomplete change management resulting in certificate invalidation. Companies should early on establish multilingual label and instruction templates, leverage GHWP member-state mutual recognition trends, perform core-document reuse and localization gap analysis, and collaborate with qualified local agents for submission, changes, and renewal.

For Chinese medical device companies, a prudent approach is first to conduct product classification and documentation gap assessment, then decide whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Target-market registration usually impacts technical files, authorized representatives, importer cooperation, label language, quality system evidence, and post-market change maintenance. If companies proceed only by a checklist of "which documents to submit," they risk deficiencies or rework in model coverage, evidence-chain consistency, label claims, and certificate control. AIMEILI recommends planning this issue within a GHWP member-state and multi-country access strategy, using a set of reusable core technical files to support localization across different markets, rather than recreating documents ad hoc for each country.

Applicable Scenarios and Core Questions

Sterilization and disinfection equipment is a category with stringent regulatory requirements, including high-temperature autoclaves, low-temperature plasma sterilizers, ethylene oxide sterilizers, steam sterilizers, and washer-disinfectors. If you plan to sell these products overseas, labels and instructions must be redeveloped according to target-country requirements, not merely mechanically translated from Chinese into English or other languages.

The core questions are: Does the target country regulate the product as a medical device? What is the risk classification? What mandatory information must appear on labels and instructions? Can the existing NMPA, CE, or FDA labels and instructions serve as a basis? If not directly usable, what are the gaps? These answers determine the workload, timeline, and compliance risk of localization.

There are three typical scenarios for companies: first, holding a domestic registration certificate and planning to enter Southeast Asia, the Middle East, or Latin America; second, holding CE or FDA documentation and wanting to expand GHWP member-state registrations; third, simultaneously launching multi-country registration with a single technical platform supporting all label and instruction versions. The localization strategy and priorities differ significantly across these scenarios.

Many companies equate "localization" with "translation," leading to repeated deficiencies or corrective actions during regulatory review, customs inspection, and post-market surveillance. Only by first understanding the target country's regulatory framework and then adjusting labels and instructions can rework be avoided.

Registration Decision Logic

First step: Determine whether the product falls under the target country's medical device regulatory scope. The definition boundary for "sterilization and disinfection equipment" varies by country; some classify sterilizers as active medical devices, others as hospital infection-control equipment, and some classify certain washer-disinfectors as general electrical appliances. Companies should consult the target country's medical device classification catalog or official decision-tree tools.

Second step: Determine the risk class and registration pathway. For example, in the United States, most sterilization equipment is Class II, requiring 510(k) or De Novo, while some may be Class I exempt; in the EU, under rules like Rule 15, they may be Class IIa or IIb; in Southeast Asian and Latin American countries, classification often references the Global Harmonization Task Force or ASEAN guidelines, but specific classification may differ. The company must confirm the pathway, whether it be listing, registration, or premarket approval.

Third step: Assess the reusability of existing documentation. If the product already has NMPA registration, CE marking, FDA clearance, or MDSAP certification, technical documentation such as performance validation, risk management, biocompatibility, and sterilization confirmation is likely reusable. However, labels and instructions must undergo localization gap analysis and cannot be copied directly.

Fourth step: Define the local agent and applicant. Most countries require non-domestic manufacturers to designate a local authorized representative or agent responsible for filing applications, receiving regulatory notices, handling adverse events, and facilitating inspections. Companies should select an agent early and have them participate in regulatory review of labels and instructions, as the agent is familiar with local language and official formats.

Fifth step: Verify post-market requirements. Contact details, registration numbers, change-notification mechanisms, and vigilance information in the instructions must align with the post-market maintenance plan. If the manufacturer address or agent information in the instructions differs from the actual registration, renewal and change approvals can be affected.

Documentation and Evidence

Label and instruction localization requires three types of documents: product baseline documentation, target-country regulatory requirements, and gap-analysis records. Product baseline includes technical instructions, user manuals, quick guides, package labels, electronic labels, and software interface text.

Target-country regulatory requirements include the country's medical device law, labeling and instruction guidelines, language requirements, units of measurement, hazardous substance labeling, electronic instruction policies, and UDI or product code rules. Companies should organize these into a comparison table and confirm each item.

The gap-analysis record is the core evidence of localization work. Companies should establish a table listing original Chinese content, English general content, target-language version, regulatory basis, reason for difference, modification date, and approver. This record is inspected during registration review and system audits.

If the product has CE or FDA documentation, symbols in CE labels, warning statements in FDA labels, and definitions per ISO 15223-1 can be referenced, but confirmation is needed whether the target country recognizes these symbols. Some countries have specific requirements for icon color or placement of "caution" or "warning," and some require safety warnings in the local language, not only English.

For sterilization validation, performance testing, and other evidence, if reusing existing reports, ensure that the device models, parameters, and operational descriptions in the instructions are consistent. For example, sterilization temperature and time described in the instructions must match the validation report; otherwise, review questions arise.

A local agent typically provides the agency agreement, power of attorney, and local registered address. These documents also support the agent information section of the instructions. Some countries require the manufacturer and agent information to be written using official grammar, without abbreviations or translation ambiguity.

Common Mistakes

• Handing translation to a general translation agency that lacks regulatory terminology understanding, leading to ambiguity in key concepts such as "sterilization cycle" or "biological indicator."
• Directly removing mandatory Chinese label content, assuming the target country has fewer requirements, while omitting information such as manufacturer name, address, date of manufacture, or expiration date.
• Ignoring the complexity of target-country languages, such as character sets and text layout for Japanese, Arabic, Thai, or Vietnamese, resulting in unreadable or unscannable printed labels.
• Failing to distinguish "instructions" from "promotional material," putting marketing language into the instructions, which regulators could deem misleading.
• Incorrect local agent information on labels, inconsistent with the agency agreement or registration certificate, causing customs clearance failure.
• Printing registration or CE numbers on the instructions before formal issuance, creating compliance issues during submission.
• Missing change management: after a major change such as factory address or agent, old label/instruction versions remain in use, resulting in non-conformities during inspections.
• Using English for all markets while ignoring local-language requirements, e.g., Arabic in many Middle Eastern countries, Russian in Russia.

Company Preparation Checklist

• Establish a label and instruction localization team including regulatory, R&D, quality, and marketing representatives.
• Confirm the target country's regulatory authority, classification result, registration pathway, and language requirements.
• Compile the product master file, listing all documents requiring localization and their version numbers.
• Create a gap-analysis template and compare original versions against target-country requirements item by item.
• Sign agreements with the local agent and obtain the local address and contact details.
• Commission a translation agency or native-language reviewer with medical and regulatory background for language conversion.
• Verify label print resolution, character sets, and symbol clarity.
• Establish a change-control process to ensure label/instruction updates are synchronized with registration changes.
• Conduct internal review and mock regulatory assessment before submission, with external experts or the agent checking.
• Retain complete localization process records as part of the technical documentation.

AIMEILI Commentary

The most common misjudgment is equating localization with translation. We have seen many projects where product performance is not an issue, but repeated label/instruction deficiencies delay registration by six to twelve months. The right approach is to commission the local agent to perform a regulatory gap analysis in the first week of the project, not wait until just before submission.

Early in the project, two things should be done: first, clarify the target country's classification and registration pathway; second, confirm language and labeling requirements. These determine workload and budget. If doing multi-country registration simultaneously, consider using a "high-requirement country" (e.g., EU or US) as the baseline, then treat other countries' special requirements as incremental additions.

Reusable documentation includes product performance validation, sterilization confirmation, risk management reports, and quality management system documentation. What must be localized are instruction language, warning statements, units of measurement, symbol meanings, agent information, and registration numbers. Also note that acceptance of electronic instructions varies by country: some allow electronic-only versions, while others require a paper copy. Companies should not violate local regulations simply to save costs.

The local agent and certificate control are critical. Certificates are usually held by the applicant, but in many cases, the agent acts on certificate changes and renewals. Companies must ensure the agency agreement specifies the timeline and legal responsibilities for certificate renewal and change notifications; otherwise, if the agency changes or terminates, the certificate may lapse, leading to product sales suspension.

Multi-country registration faces the greatest risk of repetitive documentation and deficiencies. We recommend establishing a "master label/instruction template" containing all common technical content, and for each country, create a "country-specific difference layer" controlled by a difference table. This allows efficient maintenance even when filing for a dozen countries simultaneously, reducing the risk of version chaos and deficiencies.

Frequently Asked Questions

Must the instructions for sterilization and disinfection equipment be in the target country's language?

In the vast majority of countries, the official language or at least an officially recognized language is required. For example, Indonesia requires Indonesian, Thailand requires Thai, and many Middle Eastern countries require Arabic. Some countries allow English, but usually a local-language version must also be provided. It is best to confirm language requirements with the agent before registration and prepare native-language translation and review in advance.

If I already have CE and FDA labels, can they be used directly for Southeast Asian countries?

No. CE and FDA labels reflect a certain level of regulatory rigor, but Southeast Asian countries have independent requirements for manufacturer information, agent information, registration numbers, warnings, and symbol definitions. For instance, the Philippines requires the FDA registration number on labels, while Malaysia requires local representative information. It is necessary to compare and adjust item by item.

Can the indications and disinfection targets in the instructions reuse Chinese clinical evaluation data?

Re-evaluation is required. Target countries may impose stricter restrictions on indication statements, such as not claiming to "kill all microorganisms." Companies should adjust the disinfection targets, sterilization efficacy, and scope of application described in the instructions based on the target country's intended-use guidance and clinical evidence requirements. If the original clinical evaluation is inadequate, supplementary validation or literature evaluation may be required.

How to control versions during localization to avoid confusion across different countries?

It is recommended to establish a document management system that assigns a unique document code to each country-specific version and notes the target country, registration number, effective date, and revision history in the document header. Also, stipulate in the quality management system that only versions approved through regulatory review can be used for production and sales, and all obsolete versions must be retrieved or marked.

Continue Reading

Previous: How to Determine Product Classification for Overseas Registration of Sterilization and Disinfection Equipment?

Next: How to Select a Local Agent for Overseas Registration of Monitoring Equipment?

Also read: Laboratory Equipment: How to Prepare Technical Documentation for Overseas Registration; Laboratory Equipment: Can Test Reports Be Reused for Overseas Registration; Dental Devices: How to Prepare Performance Verification Data for Overseas Registration; Implantable Products: How to Prepare Performance Verification Data for Overseas Registration; Monitoring Equipment: How to Localize Labels and Instructions for Overseas Registration; Software Medical Devices: What Are Common Reasons for Deficiencies in Overseas Registration?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundary

Content Author

AIMEILI Regulatory Editorial Team

Professional Review

AIMEILI International Medical Device Registration Project Group

Source Principle

Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience serve as supplementary judgment.

Applicability Boundary

This article is for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements from target-country regulatory authorities, testing conclusions, or legal opinions.